The sales are small relative to market cap and consistent with routine portfolio management by early investors. No immediate concern, but monitor for follow-up filings or broader insider selling trends.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $86.14entry
- T+1 · 7mo ago +1.82%α +0.61% · $87.71
- T+5 · 7mo ago +1.20%α +0.21% · $87.17
- T+20 · 6mo ago −0.64%α −6.45% · $85.59
- T+60 · 4mo ago +28.16%α +21.12% · $110.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two institutional affiliates of Atlas Venture, Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., filed notices to sell a combined 3,135 shares of Kymera Therapeutics (KYMR) stock, valued at approximately $281,742. The filings were submitted on the same day, signaling coordinated intent to divest small positions.
Key Facts
- Atlas Venture Fund X, L.P. intends to sell 2,750 shares, valued at $247,142.50.
- Atlas Venture Opportunity Fund I, L.P. intends to sell 385 shares, valued at $34,599.95.
- Total proposed sale: 3,135 shares worth $281,742.45.
- Sales are planned through Merrill Lynch on Nasdaq, with filing dates of April 15, 2026.
- Both funds are affiliated with Atlas Venture, a founding investor in Kymera.
Financial Impact
Approximately $281,742 in potential near-term selling pressure; minimal relative to Kymera's $7.3B market cap.
Risk Factors
- Perception of waning confidence if additional insiders file similar notices.
- Potential for short-term price pressure if sales execute during low liquidity periods.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (KYMR), Batch item 1 | 0001628280-26-025280 |
| Document: 0001628280-26-025280-index.html | 0001628280-26-025281 |
| Document: 0001628280-26-025280.txt | 0001628280-26-025280 |
| 144 Filing (KYMR), Batch item 4 | 0001628280-26-025281 |
| Document: 0001628280-26-025281-index.html | 0001628280-26-025280 |
| Document: 0001628280-26-025281.txt | 0001628280-26-025280 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers